May 12, 2022

In their recent bulletin, Alverno Laboratories provided updates relevant to healthcare providers. They outlined a Hepatitis C testing algorithm covering diagnosis and monitoring, where initial screening involves antibody testing, with reactive or equivocal results automatically confirmed via PCR assay. Additionally, they introduced a new testing algorithm for hospital inpatients with gastrointestinal symptoms, involving reflex testing for Clostridium difficile toxin A/B if detected on the BioFire® FilmArray® Gastrointestinal Panel. The bulletin offers guidance on test ordering to streamline the diagnostic process and ensure appropriate testing based on clinical indications.